Dilon Technologies has closed a $9 million growth capital investment from JGB Management to support expansion of its medical device portfolio, including breakthrough technology for breast cancer surgery that significantly reduces the need for repeat procedures.
The company develops medical devices for biosurgery and breast cancer treatment, with its MarginProbe device representing a significant advancement in breast cancer care. The technology enables surgeons to assess lumpectomy margins in real-time during surgery, addressing a critical challenge where patients often require additional operations when cancer cells are found at tissue margins post-surgery.
Clinical studies demonstrate MarginProbe reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal showed a 42% reduction in repeat surgeries for patients with ductal carcinoma in situ (DCIS), a common form of early-stage breast cancer.
“We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide,” said George Makhoul, CEO of Dilon Technologies. “This funding empowers us to continue delivering best-in-class innovations that improve patient care.”
The company has submitted a next-generation version of MarginProbe to the FDA, with approval anticipated by year-end. This advancement could further improve outcomes for the approximately 300,000 women diagnosed with breast cancer annually in the United States, many of whom undergo lumpectomy procedures.
Dilon’s portfolio extends beyond breast cancer technology. The company’s HEMOBLAST Bellows represents the only FDA-approved powder-form hemostatic agent specifically indicated for controlling minimal, mild, and moderate bleeding across cardiac, general, and orthopedic surgeries. The product is currently used in several hundred U.S. hospitals. The Navigator Gamma Probe product line provides radio-guided lymphatic mapping and tumor localization capabilities, with an enhanced version expected to launch by late 2025. The company also markets surgical specimen analyzers and airway management devices.
“We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide,” said Brett Cohen, CEO of JGB Management.
